ACTRN12621001677897尚未招募未知
The feasibility of a short duration, intensive, multidisciplinary, self-managed mobility program for community stroke survivors
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Eligibility criteria:
- •Clients can participate in the program if:
- •They are over 18 years of age
- •Physical or Medical readiness to participate using the Physical Activity Readiness Questionnaire (PARQ)
- •They have sufficient mobility: They achieve 3 or more in the sitting component and 2 or more in the sitting to standing component of the Motor Assessment Scale for Stroke (MAS)
- •Inclusion Criteria:
- •Participants will be included in the research study if:
- •They have nominated to participate in an intensive mobility program at the study site and meet the sites criteria as listed above
- •Have a primary diagnosis of stroke
排除标准
- •Participants will be excluded from the research study:
- •They cannot read or understand verbal or written English
- •Do not have sufficient cognition to participate in a video guided or semi-supervised exercise program (as determined by their score on a Mini Mental State Examination (MMSE) > 24/30)
研究者
相似试验
已完成
不适用
Effectiveness and feasibility of intensive short-term graded exercise programmesTopic: Generic Health Relevance and Cross Cutting ThemesSubtopic: Generic Health Relevance (all Subtopics)Disease: PaediatricsNervous System DiseasesCerebral palsyISRCTN81214142Sussex NHS Research Consortium (UK)36
进行中（未招募）
1 期
Extension Study to Evaluate how safe and tolerable the drug NBI-921352 is when used as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8ADEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-004393-62-PTeurocrine Biosciences, Inc.52
进行中（未招募）
1 期
Extension Study to Evaluate how safe and tolerable the drug NBI-921352 is when used as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).EUCTR2021-004393-62-ESeurocrine Biosciences, Inc.52
进行中（未招募）
1 期
Extension Study to Evaluate how safe and tolerable the drug NBI-921352 is when used as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8ADEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-004393-62-NLeurocrine Biosciences, Inc.52
进行中（未招募）
1 期
Extension Study to Evaluate how safe and tolerable the drug NBI-921352 is when used as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8ADEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-004393-62-DKeurocrine Biosciences, Inc.52